Psychiatric comorbidity in methamphetamine dependence

Ruth Salo, Keith Flower, Anousheh Kielstein, Martin H Leamon, Thomas E Nordahl, Gantt P. Galloway

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The primary aim of the present study was to assess the prevalence of psychiatric comorbidity in a large sample of methamphetamine (MA)-dependent subjects using a validated structured clinical interview, without limitation to sexual orientation or participation in a treatment program. The secondary aim was to assess whether the prevalence of psychiatric comorbidities varied by gender. Structured clinical interviews (SCIDs) were administered to 189 MA-dependent subjects and lifetime prevalence of DSM-IV diagnoses was assessed. Across the sample, 28.6% had primary psychotic disorders, 23.8% of which were substance-induced; 13.2% had MA-induced delusional disorders and 11.1% had MA-induced hallucinations. A substantial number of lifetime mood disorders were identified that were not substance-induced (32.3%), whereas 14.8% had mood disorders induced by substances, and 10.6% had mood disorders induced by amphetamines. Of all participants, 26.5% had anxiety disorders and 3.7% had a substance-induced anxiety disorder, all of which were induced by MA. Male subjects reported a higher percentage of MA-induced delusions compared to female abusers. Given the impact of MA psychosis and other drug-induced symptoms on hospitals and mental health services, the description and characterization of comorbid psychiatric symptoms associated with MA use is of paramount importance.

Original languageEnglish (US)
Pages (from-to)356-361
Number of pages6
JournalPsychiatry Research
Volume186
Issue number2-3
DOIs
StatePublished - Apr 30 2011

Fingerprint

Methamphetamine
Psychiatry
Comorbidity
Mood Disorders
Anxiety Disorders
Substance-Induced Psychoses
Interviews
Paranoid Schizophrenia
Amphetamines
Delusions
Hallucinations
Mental Health Services
Diagnostic and Statistical Manual of Mental Disorders
Sexual Behavior
Psychotic Disorders

Keywords

  • Gender
  • Psychiatric comorbidity
  • Stimulants
  • Substance abuse

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Psychiatric comorbidity in methamphetamine dependence. / Salo, Ruth; Flower, Keith; Kielstein, Anousheh; Leamon, Martin H; Nordahl, Thomas E; Galloway, Gantt P.

In: Psychiatry Research, Vol. 186, No. 2-3, 30.04.2011, p. 356-361.

Research output: Contribution to journalArticle

Salo, Ruth ; Flower, Keith ; Kielstein, Anousheh ; Leamon, Martin H ; Nordahl, Thomas E ; Galloway, Gantt P. / Psychiatric comorbidity in methamphetamine dependence. In: Psychiatry Research. 2011 ; Vol. 186, No. 2-3. pp. 356-361.
@article{1dcf4187fadd4078869978c67f146865,
title = "Psychiatric comorbidity in methamphetamine dependence",
abstract = "The primary aim of the present study was to assess the prevalence of psychiatric comorbidity in a large sample of methamphetamine (MA)-dependent subjects using a validated structured clinical interview, without limitation to sexual orientation or participation in a treatment program. The secondary aim was to assess whether the prevalence of psychiatric comorbidities varied by gender. Structured clinical interviews (SCIDs) were administered to 189 MA-dependent subjects and lifetime prevalence of DSM-IV diagnoses was assessed. Across the sample, 28.6{\%} had primary psychotic disorders, 23.8{\%} of which were substance-induced; 13.2{\%} had MA-induced delusional disorders and 11.1{\%} had MA-induced hallucinations. A substantial number of lifetime mood disorders were identified that were not substance-induced (32.3{\%}), whereas 14.8{\%} had mood disorders induced by substances, and 10.6{\%} had mood disorders induced by amphetamines. Of all participants, 26.5{\%} had anxiety disorders and 3.7{\%} had a substance-induced anxiety disorder, all of which were induced by MA. Male subjects reported a higher percentage of MA-induced delusions compared to female abusers. Given the impact of MA psychosis and other drug-induced symptoms on hospitals and mental health services, the description and characterization of comorbid psychiatric symptoms associated with MA use is of paramount importance.",
keywords = "Gender, Psychiatric comorbidity, Stimulants, Substance abuse",
author = "Ruth Salo and Keith Flower and Anousheh Kielstein and Leamon, {Martin H} and Nordahl, {Thomas E} and Galloway, {Gantt P.}",
year = "2011",
month = "4",
day = "30",
doi = "10.1016/j.psychres.2010.09.014",
language = "English (US)",
volume = "186",
pages = "356--361",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "2-3",

}

TY - JOUR

T1 - Psychiatric comorbidity in methamphetamine dependence

AU - Salo, Ruth

AU - Flower, Keith

AU - Kielstein, Anousheh

AU - Leamon, Martin H

AU - Nordahl, Thomas E

AU - Galloway, Gantt P.

PY - 2011/4/30

Y1 - 2011/4/30

N2 - The primary aim of the present study was to assess the prevalence of psychiatric comorbidity in a large sample of methamphetamine (MA)-dependent subjects using a validated structured clinical interview, without limitation to sexual orientation or participation in a treatment program. The secondary aim was to assess whether the prevalence of psychiatric comorbidities varied by gender. Structured clinical interviews (SCIDs) were administered to 189 MA-dependent subjects and lifetime prevalence of DSM-IV diagnoses was assessed. Across the sample, 28.6% had primary psychotic disorders, 23.8% of which were substance-induced; 13.2% had MA-induced delusional disorders and 11.1% had MA-induced hallucinations. A substantial number of lifetime mood disorders were identified that were not substance-induced (32.3%), whereas 14.8% had mood disorders induced by substances, and 10.6% had mood disorders induced by amphetamines. Of all participants, 26.5% had anxiety disorders and 3.7% had a substance-induced anxiety disorder, all of which were induced by MA. Male subjects reported a higher percentage of MA-induced delusions compared to female abusers. Given the impact of MA psychosis and other drug-induced symptoms on hospitals and mental health services, the description and characterization of comorbid psychiatric symptoms associated with MA use is of paramount importance.

AB - The primary aim of the present study was to assess the prevalence of psychiatric comorbidity in a large sample of methamphetamine (MA)-dependent subjects using a validated structured clinical interview, without limitation to sexual orientation or participation in a treatment program. The secondary aim was to assess whether the prevalence of psychiatric comorbidities varied by gender. Structured clinical interviews (SCIDs) were administered to 189 MA-dependent subjects and lifetime prevalence of DSM-IV diagnoses was assessed. Across the sample, 28.6% had primary psychotic disorders, 23.8% of which were substance-induced; 13.2% had MA-induced delusional disorders and 11.1% had MA-induced hallucinations. A substantial number of lifetime mood disorders were identified that were not substance-induced (32.3%), whereas 14.8% had mood disorders induced by substances, and 10.6% had mood disorders induced by amphetamines. Of all participants, 26.5% had anxiety disorders and 3.7% had a substance-induced anxiety disorder, all of which were induced by MA. Male subjects reported a higher percentage of MA-induced delusions compared to female abusers. Given the impact of MA psychosis and other drug-induced symptoms on hospitals and mental health services, the description and characterization of comorbid psychiatric symptoms associated with MA use is of paramount importance.

KW - Gender

KW - Psychiatric comorbidity

KW - Stimulants

KW - Substance abuse

UR - http://www.scopus.com/inward/record.url?scp=79952359698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952359698&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2010.09.014

DO - 10.1016/j.psychres.2010.09.014

M3 - Article

C2 - 21055832

AN - SCOPUS:79952359698

VL - 186

SP - 356

EP - 361

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 2-3

ER -